Life expectancy of patients with deep-seated postoperative <i>S. aureus</i> infections.

a<p>17 patients (46%) are included in estimate of the cost of a postoperative surgical site infection.</p

Effect of suboptimal adherence to preoperative <i>S. aureus</i> screening and test sensitivity on cost per life year gained (discounted) per 1000 patients for different screening scenarios.

<p>Scenario 1 is treatment of <i>S. aureus</i> carriers identified by screening; scenario 2 is treatment of <i>S. aureus</i> carriers identified by screening <i>plus</i> treatment of all patients that were not screened. In scenario 1 the life years gained and costs increase, or decrease, at a constant rate resulting in an invariable cost per life years gained. Note the negative costs on the y-axis representing cost-savings.</p

Direct health care costs of patients readmitted because of a postoperative surgical site infection between 2001 and 2010.

a<p>Missing information on 8 patients.</p>b<p>Missing information on 1 patient.</p>c<p>Missing information on 3 patients.</p>d<p>Costs of antibiotic treatment were not included.</p

Cost-analysis of different strategies per 1000 patients undergoing prosthetic joint or cardiopulmonary surgery.

<p>Cost-analysis of different strategies per 1000 patients undergoing prosthetic joint or cardiopulmonary surgery.</p

Effect of suboptimal adherence to preoperative <i>S. aureus</i> screening on total costs and life years gained (discounted) per 1000 patients for scenario 1 (only identified <i>S. aureus</i> carriers are treated) and scenario 2 (identified <i>S. aureus</i> carriers and non-screened patients are treated).

<p>Note the negative costs on the y-axis representing cost-savings.</p

Parameters used in cost-effectiveness analysis.

<p>Parameters used in cost-effectiveness analysis.</p

Effect of suboptimal adherence to preoperative <i>S. aureus</i> screening and treatment effectiveness on cost per life year gained (discounted) per 1000 patients for different screening scenarios.

<p>Scenario 1 is treatment of <i>S. aureus</i> carriers identified by screening; scenario 2 is treatment of <i>S. aureus</i> carriers identified by screening <i>plus</i> treatment of all patients that were not screened. In scenario 1 the life years gained and costs increase, or decrease, at a constant rate resulting in an invariable cost per life years gained. Note the negative costs on the y-axis representing cost-savings.</p